使用强化胰岛素的成人2型糖尿病患者瞬时血糖监测系统的成本计算-英国视角

Q2 Medicine
European Endocrinology Pub Date : 2018-09-01 Epub Date: 2018-09-10 DOI:10.17925/EE.2018.14.2.86
Richard Hellmund, Raimund Weitgasser, Deirdre Blissett
{"title":"使用强化胰岛素的成人2型糖尿病患者瞬时血糖监测系统的成本计算-英国视角","authors":"Richard Hellmund,&nbsp;Raimund Weitgasser,&nbsp;Deirdre Blissett","doi":"10.17925/EE.2018.14.2.86","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> Estimate the costs associated with flash glucose monitoring as a replacement for routine self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus (T2DM) using intensive insulin, from a UK National Health Service (NHS) perspective. <b>Methods:</b> The base-case cost calculation used the frequency of SMBG and healthcare resource use observed in the REPLACE trial. Scenario analyses considered SMBG at the flash monitoring frequencies observed in the REPLACE trial (8.3 tests per day) and a real-world analysis (16 tests per day). <b>Results:</b> Compared with 3 SMBG tests per day, flash monitoring would cost an additional £585 per patient per year, offset by a £776 reduction in healthcare resource use, based on reductions in emergency room visits (41%), ambulance call-outs (66%) and hospital admissions (77%) observed in the REPLACE trial. Per patient, the estimated total annual cost for flash monitoring was £191 (13.4%) lower than for SMBG. In the scenarios based on acquisition cost alone, flash monitoring was cost-neutral versus 8.3 SMBG tests per day (5% decrease) and cost-saving at higher testing frequencies. <b>Conclusion:</b> From a UK NHS perspective, for patients with T2DM using intensive insulin, flash monitoring is potentially cost-saving compared with routine SMBG irrespective of testing frequency.</p>","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"14 2","pages":"86-92"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/ee/euendo-14-86.PMC6182928.pdf","citationCount":"11","resultStr":"{\"title\":\"Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin - a UK Perspective.\",\"authors\":\"Richard Hellmund,&nbsp;Raimund Weitgasser,&nbsp;Deirdre Blissett\",\"doi\":\"10.17925/EE.2018.14.2.86\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> Estimate the costs associated with flash glucose monitoring as a replacement for routine self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus (T2DM) using intensive insulin, from a UK National Health Service (NHS) perspective. <b>Methods:</b> The base-case cost calculation used the frequency of SMBG and healthcare resource use observed in the REPLACE trial. Scenario analyses considered SMBG at the flash monitoring frequencies observed in the REPLACE trial (8.3 tests per day) and a real-world analysis (16 tests per day). <b>Results:</b> Compared with 3 SMBG tests per day, flash monitoring would cost an additional £585 per patient per year, offset by a £776 reduction in healthcare resource use, based on reductions in emergency room visits (41%), ambulance call-outs (66%) and hospital admissions (77%) observed in the REPLACE trial. Per patient, the estimated total annual cost for flash monitoring was £191 (13.4%) lower than for SMBG. In the scenarios based on acquisition cost alone, flash monitoring was cost-neutral versus 8.3 SMBG tests per day (5% decrease) and cost-saving at higher testing frequencies. <b>Conclusion:</b> From a UK NHS perspective, for patients with T2DM using intensive insulin, flash monitoring is potentially cost-saving compared with routine SMBG irrespective of testing frequency.</p>\",\"PeriodicalId\":38860,\"journal\":{\"name\":\"European Endocrinology\",\"volume\":\"14 2\",\"pages\":\"86-92\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/ee/euendo-14-86.PMC6182928.pdf\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/EE.2018.14.2.86\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/9/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2018.14.2.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/9/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 11

摘要

目的:从英国国民健康服务(NHS)的角度,评估使用强化胰岛素治疗的2型糖尿病(T2DM)患者使用瞬时血糖监测替代常规自我血糖监测(SMBG)的相关成本。方法:基础病例成本计算采用在REPLACE试验中观察到的SMBG和医疗资源使用频率。情景分析考虑了REPLACE试验中观察到的闪光监测频率下的SMBG(每天8.3次测试)和实际分析(每天16次测试)。结果:与每天3次SMBG检测相比,flash监测每位患者每年将额外花费585英镑,但根据REPLACE试验中观察到的急诊室就诊(41%)、救护车呼叫(66%)和住院(77%)的减少,医疗资源使用减少了776英镑。每位患者,闪光灯监测的估计年度总成本比SMBG低191英镑(13.4%)。在仅基于采集成本的情况下,与每天8.3次SMBG测试(减少5%)相比,flash监测的成本中性,并且在更高的测试频率下可以节省成本。结论:从英国NHS的角度来看,对于使用强化胰岛素的T2DM患者,与常规SMBG相比,无论检测频率如何,闪光监测都可能节省成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin - a UK Perspective.

Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin - a UK Perspective.

Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin - a UK Perspective.

Aims: Estimate the costs associated with flash glucose monitoring as a replacement for routine self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus (T2DM) using intensive insulin, from a UK National Health Service (NHS) perspective. Methods: The base-case cost calculation used the frequency of SMBG and healthcare resource use observed in the REPLACE trial. Scenario analyses considered SMBG at the flash monitoring frequencies observed in the REPLACE trial (8.3 tests per day) and a real-world analysis (16 tests per day). Results: Compared with 3 SMBG tests per day, flash monitoring would cost an additional £585 per patient per year, offset by a £776 reduction in healthcare resource use, based on reductions in emergency room visits (41%), ambulance call-outs (66%) and hospital admissions (77%) observed in the REPLACE trial. Per patient, the estimated total annual cost for flash monitoring was £191 (13.4%) lower than for SMBG. In the scenarios based on acquisition cost alone, flash monitoring was cost-neutral versus 8.3 SMBG tests per day (5% decrease) and cost-saving at higher testing frequencies. Conclusion: From a UK NHS perspective, for patients with T2DM using intensive insulin, flash monitoring is potentially cost-saving compared with routine SMBG irrespective of testing frequency.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Endocrinology
European Endocrinology Medicine-Endocrinology, Diabetes and Metabolism
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信